A synthetic macromolecule for sentinel node detection: (99m)Tc-DTPA-mannosyl-dextran.

UNLABELLED We report the synthesis and preliminary biologic testing of a synthetic macromolecule, (99m)Tc-diethylenetriaminepentaacetic acid (DTPA)--mannosyl-dextran, for sentinel node detection. METHODS Synthesis started with a 2-step process that attaches a high density of amino-terminated leashes to a dextran backbone. Allyl-bromide was reacted with pharmaceutical-grade dextran to yield allyl-dextran. After diafiltration with water, filtration, and lyophilization, the product was reacted with aminoethanethiol and ammonium persulfate. The resulting amino-conjugated dextran was dialyzed, filtered, and lyophilized. The mixed anhydride method was used to attach DTPA; after dialysis, filtration, and lyophilization, 2-imino-2-methoxyethyl-1-D-mannose was used to attach the receptor substrate. The molecular diameter was measured by dynamic light scattering. Amino, mannose, and DTPA densities were measured by trinitrobenzene sulfonate assay, sulfuric acid/phenol assay, and inductively coupled plasma spectroscopy of gadolinium-DTPA-mannosyl-dextran, respectively. Receptor affinity was measured by Scatchard assay of rabbit liver. Axillary, popliteal, and iliac lymph nodes and each injection site were assayed for radioactivity at 1 and 3 h after injection of approximately 3.7 MBq (0.050 mL) (99m)Tc-DTPA-mannosyl-dextran (0.22 nmol) or filtered (99m)Tc-sulfur colloid into the foot pads. Four animals were studied at each time point. RESULTS DTPA-mannosyl-dextran had a molecular weight of 35,800 g/mol and a molecular diameter of 7.1 nm. The final amine, mannose, and DTPA densities were 23, 55, and 8 mol per dextran. Labeling yields were in excess of 98% and stable for 6 h. Specific activities of 74 x 10(6) GBq/mol were achieved. The equilibrium dissociation constant for binding to the mannose-terminated glycoprotein receptor was 0.12 +/- 0.07 nmol/L. The popliteal extraction at both 1 h and 3 h was significantly (P < 0.05) higher for (99m)Tc-DTPA-mannosyl-dextran (90.1% +/- 10.7% and 97.7% +/- 2.0%, respectively) than for filtered (99m)Tc-sulfur colloid (78.8 +/- 6.5 and 67.4% +/- 26.8%, respectively). (99m)Tc-DTPA-mannosyl-dextran exhibited significantly faster injection site clearance than did filtered (99m)Tc-sulfur colloid. The (99m)Tc-DTPA-mannosyl-dextran percentage injected dose (%ID) for the front and rear paws was 52.6 +/- 10.5 and 52.3 +/- 8.0 at 1 h and 45.7 +/- 8.5 and 43.6 +/- 8.2 at 3 h after administration. The filtered (99m)Tc-sulfur colloid %ID for the front and rear paws was 70.4 +/- 11.0 and 66.3 +/- 15.1 at 1 h and 55.5 +/- 7.8 and 66.9 +/- 8.5 at 3 h. Lymph node accumulation of each agent at either 1 or 3 h was not significantly different. CONCLUSION (99m)Tc-DTPA-mannosyl-dextran is a receptor-based sentinel node radiotracer that exhibits the desired properties of rapid injection site clearance and low distal node accumulation. This molecule is the first member of a new class of diagnostic agents based on a macromolecular backbone with a high density of sites for the attachment of substrates and imaging reporters.

[1]  M. Rusckowski,et al.  Different chelators and different peptides together influence the in vitro and mouse in vivo properties of 99Tcm , 2001, Nuclear medicine communications.

[2]  E. W. Meijer,et al.  Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[3]  A. Giuliano,et al.  Role of sentinel lymph node dissection in breast cancer , 2000, Annals of medicine.

[4]  J. Thompson,et al.  Sentinel lymph node detection and imaging. , 1999, European journal of nuclear medicine.

[5]  G. S. Mijnhout,et al.  Radiopharmaceuticals in sentinel lymph-node detection – an overview , 1999, European Journal of Nuclear Medicine.

[6]  P. Ell,et al.  Sentinel lymph node detection and imaging , 1999, European Journal of Nuclear Medicine.

[7]  R. Foster,et al.  The sentinel node in breast cancer--a multicenter validation study. , 1998, The New England journal of medicine.

[8]  M. Ross,et al.  Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. , 1998, Surgery.

[9]  E. Wisner,et al.  Sentinel node imaging via a nonparticulate receptor-binding radiotracer. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  D. Eshima,et al.  Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. , 1997, Seminars in nuclear medicine.

[11]  C. Porter Drug delivery to the lymphatic system. , 1997, Critical reviews in therapeutic drug carrier systems.

[12]  J. Carlsson,et al.  Development and in vitro studies of epidermal growth factor-dextran conjugates for boron neutron capture therapy. , 1996, Bioconjugate chemistry.

[13]  D. Reintgen,et al.  The Use of Intraoperative Radiolymphoscintigraphy for Sentinel Node Biopsy in Patients with Malignant Melanoma , 1996, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[14]  S. Dumitriu Polysaccharides in Medicinal Applications , 1996 .

[15]  C W Cruse,et al.  Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. , 1996, Annals of surgery.

[16]  M. Buonocore,et al.  A molecular receptor-binding contrast agent for magnetic resonance imaging of the liver. , 1995, Academic Radiology.

[17]  D. Vera,et al.  In vitro quantification of asialoglycoprotein receptor density from human hepatic microsamples. , 1994, Methods in enzymology.

[18]  L. Meurling,et al.  Preparation of sulfhydrylborane-dextran conjugates for boron neutron capture therapy. , 1993, Bioconjugate chemistry.

[19]  D. Vera Gallium-labeled deferoxamine-galactosyl-neoglycoalbumin: a radiopharmaceutical for regional measurement of hepatic receptor biochemistry. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[21]  M. Kudo,et al.  [Phase III multi-center clinical study on 99mTc-GSA, a new agent for functional imaging of the liver]. , 1992, Kaku igaku. The Japanese journal of nuclear medicine.

[22]  James R. Dewald,et al.  A New Class of Polymers: Starburst-Dendritic Macromolecules , 1985 .

[23]  K. Krohn,et al.  Tc-99m galactosyl-neoglycoalbumin: in vitro characterization of receptor-mediated binding. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  C. Lazarus Chromatography of Technetium-99m Radiopharmaceuticals - A Practical Guide , 1984 .

[25]  R K Jain,et al.  Extravascular diffusion in normal and neoplastic tissues. , 1984, Cancer research.

[26]  J. Tisnado,et al.  Use of isosulfan blue for identification of lymphatic vessels: experimental and clinical evaluation. , 1982, AJR. American journal of roentgenology.

[27]  T. Kawasaki,et al.  Mannan-binding protein in lymphoid tissues of rats. , 1980, Journal of biochemistry.

[28]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[29]  L. Thorén Dextran as a plasma volume substitute. , 1978, Progress in clinical and biological research.

[30]  G. Krejcarek,et al.  Covalent attachment of chelating groups to macromolecules. , 1977, Biochemical and biophysical research communications.

[31]  M. Krantz,et al.  2-Imino-2-methoxyethyl 1-thioglycosides: new reagents for attaching sugars to proteins. , 1976, Biochemistry.

[32]  B. Persson,et al.  Gel chromatography column scanning for the analysis of 99mTc-labelled compounds. , 1974, Journal of chromatography.

[33]  C. L. Yuan,et al.  Synthesis of 1-thioaldosides having an amino group at the aglycon terminal , 1973 .

[34]  W. Kelly,et al.  Pharmaceutical quality of technetium-99m sulfur colloid. , 1973, American journal of hospital pharmacy.

[35]  R. Fields [38] The rapid determination of amino groups with TNBS. , 1972, Methods in enzymology.

[36]  F. Smith,et al.  COLORIMETRIC METHOD FOR DETER-MINATION OF SUGAR AND RELATED SUBSTANCE , 1956 .

[37]  M. BÁRCZAI-MARTOS,et al.  Preparation of Acetobrome-Sugars , 1950, Nature.

[38]  A. Hirschfelder THE UNITED STATES PHARMACOPEIAL CONVENTION , 1930 .

[39]  R. Hatcher THE UNITED STATES PHARMACOPEIA. , 1908 .